Showing results (21-30 of 126) with videos related to
Sort By:
Pageof 13
Pharmaceutical Science Advances|January 19, 2026
Research progress of 3D printing technology in the field of oral materialsKhan Rajib Hossain, Dipika Ramdas Kalambhe, M Abdul Jalil, et al.Pharmaceutical Science Advances|January 19, 2026
Rational design of siRNA-based delivery systems for effective treatment of brain diseasesDailin Lu, Yonghang Sun, Yuxia Luan, et al.Pharmaceutical Science Advances|January 19, 2026
Potential application of sucrose acetate isobutyrate, and glyceryl monooleate for nanonization and bioavailability enhancement of rivaroxaban tabletsAdam A Al-Shoubki, Mahmoud H Teaima, Rehab Abdelmonem, et al.Pharmaceutical Science Advances|January 19, 2026
Structure, functions, and recent advances in the development of SIRT2 inhibitorsJunxin Xue, Xuben Hou, Hao FangPharmaceutical Science Advances|March 9, 2026
Mechanisms of tumor cell evasion from NK cell-mediated killing and advances in NK cell-based cancer immunotherapyRulin Zheng, Zhuqing Wang, Baodi Zhang, et al.Pharmaceutical Science Advances|May 4, 2026
Fufang Huangbo Formula mitigates myeloproliferative neoplasms by activating p53/p21 signaling axis and inhibiting STAT3 and NF-κB signaling pathwaysMingjie Liu, Yanxia Li, Chengxue Qin, et al.Pharmaceutical Science Advances|April 17, 2026
NAD+ precursor supplementation reverses CD36-mediated lipid accumulation and ferroptosis to restore antitumor function of NK cells in DLBCLLizhi Shi, Xuezhu Huang, Xiao Han, et al.Pharmaceutical Science Advances|September 12, 2026
Corrigendum to "Protective effects and metabolomics analysis of dihydromyricetin on cyclophosphamide-induced hepatotoxicity in mice" [Pharm. Sci. Adv. 3 (2025) 100063]Fei Teng, Haina WangPharmaceutical Science Advances|October 12, 2026
Xiangsha Liujunzi Tang: A promising traditional Chinese herbal formula for healing gastric mucosal injury through pyroptosis pathway modulationQifang Sun, Xinying Yi, Shunhua Zhou, et al.Pharmaceutical Science Advances|October 20, 2026
Corrigendum to "Dual-targeting liposomal delivery of sorafenib and docetaxel for enhanced synergistic therapy in advanced hepatocellular carcinoma" [Pharmaceut. Sci. Adv. 2 (2024) 100046]Yawen Yao, Yue Hu, Xinwang Meng, et al.Pageof 13